Neuronetics (STIM) Stock
Medical device maker for brain stimulation therapy. Here's the price, business snapshot, and what's worth knowing about Neuronetics in October 2026.
Neuronetics Inc (ticker STIM) is a medical‑device company that develops and commercialises non‑invasive neurostimulation systems. Its flagship product, the NeuroStar Transcranial Magnetic Stimulation (TMS) System, is used primarily to treat major depressive disorder and related indications. The company earns revenue from device sales, clinical consumables, service contracts, training and, in some markets, clinic partnerships or leasing arrangements. With a market capitalisation of roughly $190.4m, Neuronetics is a small‑cap healthcare business: potential upside includes broader clinical adoption, expanded regulatory approvals and improved reimbursement, while risks include limited product diversification, competitive neuromodulation technologies, reimbursement uncertainty and the regulatory and commercial hurdles common to medical‑device firms. Investors should note small‑cap volatility and that past performance does not predict future returns. This content is general educational information only and not personal financial advice; suitability depends on an investor’s objectives and risk tolerance and you may wish to seek independent advice.
Neuronetics (STIM) Stock Forecast
Analyst price target, next 12 months
$6.60
+205.6% vs today's $2.16
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Neuronetics have a consensus 12-month target of $6.60, above the current price of $2.16.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Neuronetics Inc. stock due to significant potential for price increase.
Financial Health
Neuronetics is generating solid revenue, cash flow, and profit margins, indicating good financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Adoption & Growth
Broader clinical adoption and better reimbursement could lift sales, though uptake varies by region and payer coverage and performance can differ.
Innovation Programme
Ongoing clinical studies aim to expand indications and improve outcomes; technical progress and regulatory approvals will shape future prospects.
Market & Competition
Competes with other neuromodulation technologies and pharmacological treatments; reimbursement and competitor advances are important risks to monitor.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
